PRVL News

June is seeing a wave of biotech IPOs. Five priced last week, and four more are on the IPO calendar for this week.   Recent biotech IPOs have mostly underperformed, though 2 are up +100% ...read more

Slack's (WORK) widely-covered direct listing was hailed as a success. Slack opened on Thursday at $38.50, well above the NYSE's "reference price" of $26, and more than triple its last round less than a year ago. And yet, new public investors ended the week with losses. The stock closed Friday at $37.22, down 3.3% from the opening trade. With millions of users...read more

Prevail Therapeutics, an early stage biotech developing gene therapies for neurodegenerative diseases, raised $125 million by offering 7.4 million shares at $17, the midpoint of the $16 to $18 range. Prevail Therapeutics plans to list on the Nasdaq under the symbol PRVL. Morgan Stanley, BofA Merrill Lynch and Cowen acted as lead managers on the deal....read more

Formed by OrbiMed, the Silverstein Foundation for Parkinson's with GBA, and a Columbia University neurologist, Prevail (PRVL) is applying gene therapies to genetic subsets of neurodegenerative diseases, including Parkinson's Disease (PD). It’s using the same technology deployed by Novartis in their recently approved super expensive ($2 million) therapy Zolgensma for...read more